Medtronic Hugo Robot Gains FDA Clearance for General Surgery

What happened
On November 17, 2026, Medtronic announced that its Hugo robotic-assisted surgery system received clearance from the U.S. Food and Drug Administration for use in general surgery. This expands Hugo's approved use in the United States from only urology to now include a wide range of upper- and lower-abdominal procedures. The FDA clearance allows hospitals to use Hugo for operations such as cholecystectomy, gastric bypass, hernia repairs, and appendectomy. The system includes modular hardware and AI-supported tools for reviewing surgeries after they are performed.
Key details
- FDA clearance for general surgery granted on November 17, 2026
- Covers procedures like cholecystectomy, Roux-en-Y gastric bypass, ventral and inguinal hernia repair, small-bowel resection, and appendectomy
- Medtronic estimates these procedures account for about 3.5 million surgeries per year in the U.S.
- Hugo's modular design allows teams to use only the needed robotic arms for each operation
- AI-powered postoperative review tools are included, but do not control the surgical instruments
Why it matters
Hospitals and surgical teams in the U.S. can now use one robotic platform for over half of all soft-tissue surgeries, potentially streamlining equipment use and training. This change gives hospitals more flexibility in managing surgical capacity and may affect purchasing and operational decisions. Medtronic’s expanded clearance also increases its commercial opportunity in the U.S. surgical robotics market.
